Form 4: ESSA Pharma Director Richard Glickman Reports Transaction

Director Richard Glickman reports a transaction involving ESSA Pharma Inc. shares and options.

Summary

• On April 24, 2024, Richard Glickman, a director of ESSA Pharma Inc., reported a transaction.
• Glickman disposed of 3,750 common shares at a price of $4.9.
• Following the transaction, Glickman directly owns 43,240 common shares.
• Glickman also disposed of 3,750 options with an exercise price of $4.9, originally granted on March 21, 2022, and expiring on May 21, 2024.

Sentiment

Score: 5

Explanation: This is a neutral report of a transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
• The information provided is consistent with the level of detail expected in such filings, similar to those of directors at comparable pharmaceutical companies.

Stakeholder Impact

• The transaction could have a minor impact on shareholders, as insider transactions are often scrutinized for signals about the company's future performance.

Key Dates